2-Formoxycyclohexanol | 56207-46-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Formoxycyclohexanol
• 英文别名: 1,2-Cyclohexanediol, 1-formate；(2-hydroxycyclohexyl) formate
• CAS: 56207-46-6
• 化学式: C₇H₁₂O₃
• 分子量: 144.17
• InChiKey: MVFAXQCWBIXUGE-UHFFFAOYSA-N

物化性质

• 沸点：
  229.2±29.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1,2-环己二醇 在 硫酸 作用下， 以 乙醚 为溶剂， 反应 14.0h， 生成 2-Formoxycyclohexanol
  参考文献：
  名称：

  General Method for the Formylation of Alcohols with Dimethylformamide: An Extension of the Vilsmeier-Haack Reaction

  摘要：

  DOI：

  10.1055/s-1985-31228

文献信息

• [EN] ANTIMICROBIAL AGENTS<br/>[FR] AGENTS ANTIMICROBIENS
  申请人：UNIV WARWICK

  公开号：WO2018193273A1

  公开（公告）日：2018-10-25

  The invention provides novel analogues of enacyloxin Ha and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs. Such compounds are effective in the treatment of infections caused by Gram-negative bacteria such as Acinetobacter baumannii. Compounds in accordance with the invention include those of formula (A), and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs: In formula (A): X is 0 or NRx (where R* is either H or C1-3 alkyl, e.g. CH3); R1 is a 5- or 6-membered, saturated or unsaturated, carbocyclic ring optionally substituted by one or more substituents, or R1 is an optionally substituted straight-chained or branched C-1-6 alkyl group (e.g. C1-3 alkyl group); R2 is H, F, CI, Br, I or CH3; R3 is H or OH; R8 is a straight-chained or branched C1-8 alkyl group (e.g. a C1-6 aikyl group); Y is one of the following groups: (wherein each * denotes the point of attachment of the group to the remainder of the molecule; R9 is H, F, CI, Br or I; R4 and R5 are independently selected from H and OH, or R4 and R5 together are =0, preferably R4 is H and R5 is OH; R6 is H, F, CI, Br, I or CH3; R7 is H and R7' is OH, or R7 and R7' together are =0, preferably R7 is H and R7' is OH); and each— independently represents an optional bond (i.e. each of C2-C3, C4-C5, C6-C7, C8-C9 and C10-C11 are independently either C-C (single) or C=C (double) bonds).

  这项发明提供了恩氨环素Ha的新型类似物及其药学上可接受的盐、代谢物、同分异构体（例如立体异构体）和前药。这些化合物在治疗由革兰氏阴性细菌引起的感染方面具有有效性，如包括鲍曼不动杆菌在内。符合该发明的化合物包括式（A）的化合物及其药学上可接受的盐、代谢物、同分异构体（例如立体异构体）和前药：在式（A）中：X为0或NRx（其中R*为H或C1-3烷基，例如CH3）；R1为一个5-或6-成员的、饱和或不饱和的、碳环，可选择地由一个或多个取代基取代，或R1为一个可选择地取代的直链或支链C-1-6烷基基团（例如C1-3烷基基团）；R2为H、F、Cl、Br、I或CH3；R3为H或OH；R8为一个直链或支链C1-8烷基基团（例如C1-6烷基基团）；Y为以下各组中的一个：（其中每个*表示该组与分子其余部分的连接点；R9为H、F、Cl、Br或I；R4和R5分别独立选择自H和OH，或R4和R5一起为=0，优选R4为H且R5为OH；R6为H、F、Cl、Br、I或CH3；R7为H且R7'为OH，或R7和R7'一起为=0，优选R7为H且R7'为OH）；每个—独立表示一个可选键（即C2-C3、C4-C5、C6-C7、C8-C9和C10-C11中的每一个独立地是C-C（单）或C=C（双）键）。
• Process for preparing acylated esters of hydroxy carboxylates
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0002872A1

  公开（公告）日：1979-07-11

  A process for esterifying and acylating hydroxycarboxylate compounds in an organonitrile reaction medicine comprising the steps of contacting said compounds with an esterification agent-and thereafter acylating by adding an acylating agent to the reaction medium.

  一种在有机腈反应药剂中对羟基羧酸化合物进行酯化和酰化的工艺，包括以下步骤：将所述化合物与酯化剂接触，然后通过向反应介质中添加酰化剂进行酰化。
• Film touch sensor and structure including the same
  申请人：DONGWOO FINE-CHEM CO., LTD.

  公开号：US11180585B2

  公开（公告）日：2021-11-23

  A film touch sensor is prepared by performing a process in which a separation layer made of a specific component is formed on a carrier substrate, and an insulation film is formed on a transparent conductive film pattern, which is used as a planarization layer, an adhesive layer or a base layer.

  薄膜式触摸传感器的制备过程是：在载体基板上形成由特定成分制成的分离层，并在透明导电薄膜图案上形成绝缘膜，该图案用作平面化层、粘合层或基底层。
• 13-Methyl erythromycin derivatives
  申请人：——

  公开号：US20030100518A1

  公开（公告）日：2003-05-29

  The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 17 , R f , A, X, and Y are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formulas 1, methods of using the compounds of formula 1 in the treatment of infections and methods of preparing the compounds of formula 1.

  本发明涉及式 1 的化合物 1 及其药学上可接受的盐、原药和溶液，其中 R 1 , R 2 , R 3 , R 4 , R 5 , R 17 , R f A、X 和 Y 如本文所定义。本发明还涉及含有式 1 化合物的药物组合物、使用式 1 化合物治疗感染的方法以及制备式 1 化合物的方法。
• Engineered biosynthesis of novel polyenes
  申请人：Caffrey Patrick John

  公开号：US20060073574A1

  公开（公告）日：2006-04-06

  The complete DNA sequence of the gene cluster encoding the polypeptides responsible for the biosynthesis of the polyene antibiotic amphotericin of S. nodosus is provided. Engineered alteration of the amphC) gene so as to eliminate production of amphotericin A in favour of the more active form amphotericin B. as well as the production of amphotericin analogues having altered characteristics, is enabled by manipulation of the sequences of the cluster.

  编码结核杆菌多烯抗生素两性霉素生物合成多肽的基因簇的完整 DNA 序列 结核杆菌 提供。通过操作该基因簇的序列，可以改变 amphC）基因，从而消除两性霉素 A 的生产，转而生产活性更强的两性霉素 B，并生产出特性有所改变的两性霉素类似物。